FDA approves Arcutis' skin foam for seborrheic dermatitis

The US Food and Drug Administration (FDA) has approved a topical foam developed by Arcutis Biotherapeutics and branded as Zoryve for the skin condition seborrheic dermatitis in people aged nine years and up.

Related Keywords

Pennsylvania ,United States ,China , ,Particle Sciences ,Sterling Pharma Solutions ,Partners Group ,Particle Science ,Snapdragon Chemistry ,Clinical Development ,Drug Delivery ,Linical Evolution ,Fda ,Food And Drug Administration ,Small Molecule Drugs ,